Core Outcome Measures in Effectiveness Trials

Developing a Core Outcome Set in adjuvant clinical trials of Chinese patent medicine for advanced non-small cell lung cancer

General Information

Advanced non-small cell lung cancer is one of the most common diseases worldwide. As the first-line treatment, chemotherapy could result in some side effects.
Some evidence show Chinese patent medicine have potential advantages in dealing with these questions above. However, because the heterogeneity in selection and reporting of outcomes, it could be difficult to combine the results of different studies to make decision about the best treatments.
A solution to these problems is the development of a core outcome set (COS). This is the minimum set of outcomes that should be studied and reported in adjuvant clinical trials of Chinese patent medicine for advanced non-small cell lung cancer.
This project aims to develop a core outcome set that can be used to assess the effectivity and safety of Chinese patent medicine in adjuvant clinical trials for advanced non-small cell lung cancer.

Jingbo Zhai,Jinhua Si,Hongcai Shang

Further Study Information

Current Stage:
January 2017 - 2019
Funding source(s):
None stated

Health Area

Disease Category

Disease Name
Advanced cancer and advanced non-malignant illnesses
Lung cancer
Non-small-cell lung cancer (NSCLC)

Target Population

Age Range
18 - 100


Nature / type of Intervention


Consensus conference
Delphi process
Systematic review

Stakeholders Involved

Clinical experts
Conference participants
Consumers (patients)

Study Type

COS for clinical trials or clinical research
COS for practice

The site uses cookies, some may have been set already. Please refer to our privacy policy & cookie usage statement.
If you continue to use the site we'll assume you're happy to accept the cookies.